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Genetically Determined Partial Complement C4
Deficiency States Are Not Independent Risk
Factors for SLE in UK and Spanish Populations
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and Michelle M.A. Fernando1,*
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease. Complete deficiency of complement component C4
confers strong genetic risk for SLE. Partial C4 deficiency states have also shown associationwith SLE, but despitemuch effort over the last
30 years, it has not been established whether this association is primarily causal or secondary to long-range linkage disequilibrium. The
complement C4 locus, located in the major histocompatibility complex (MHC) class III region, exhibits copy-number variation (CNV)
and C4 itself exists as two paralogs, C4A and C4B. In order to determine whether partial C4 deficiency is an independent genetic risk
factor for SLE, we investigatedC4CNV in the context ofHLA-DRB1 andMHC region SNP polymorphism in the largest andmost compre-
hensive complement C4 study to date. Specifically, we genotyped 2,207 subjects of northern and southern European ancestry (1,028 SLE
cases and 1,179 controls) for totalC4, C4A, andC4B gene copy numbers, and the loss-of-functionC4 exon 29 CT indel.We usedmultiple
logistic regression to determine the independence ofC4CNV from known SNP andHLA-DRB1 associations.We clearly demonstrate that
genetically determined partial C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations. These results
are further corroborated by the lack of association shown by the C4A exon 29 CT insertion in either cohort. Thus, although complete
homozygous deficiency of complement C4 is one of the strongest genetic risk factors for SLE, partial C4 deficiency states do not inde-
pendently predispose to the disease.Introduction
Systemic lupus erythematosus ([SLE] also known as lupus
[MIM 152700]) is a chronic, multisystem, clinically hetero-
geneous autoimmunedisease characterized by the presence
of autoantibodies directed against nuclear and cellular
components, complement activation, and immune com-
plex deposition resulting in tissue inflammation and organ
damage. There is a strong and complex yet incompletely
understood genetic component to disease susceptibility.
SNP-based genome-wide association studies have shown
that polymorphisms within the major histocompatibility
complex (MHC) region, located on the short arm of chro-
mosome 6, confer the greatest genetic risk for SLE.1–3 The
classical MHC region comprises three subregions: the telo-
meric class I region, the centromeric class II region, and the
intervening class III region. The MHC class I and class II
regions encode the human leucocyte antigen (HLA) class I
and class II molecules involved in antigen presentation to
T lymphocytes.4 Genetic variantswithin classical HLA class
I and HLA class II molecules as well as deficiency states of
complement C4, encoded in the class III region of the
MHC, were among the first to show association with SLE
in the early 1970s.5–7 Investigation of MHC associations
with SLE has been hampered by a number of factors,
including long-range linkage disequilibrium (LD) across
disease-associated haplotypes, high polymorphism, copy-
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reside within the class II alleles, HLA-DRB1*03:01 (DR3)
and HLA-DRB1*15:01 (DR2) and their respective extended
haplotypes in European populations.8
The complement C4 locus is structurally complex: C4
genes show significant copy-number variation (CNV)
because of segmental duplication of the RCCX module.
The module spans four genes (from which the name is
derived): STK19 (also known as RP1, a serine/threonine
protein kinase [MIM 604977]), complement C4, CYP21A2
(cytochrome P450 steroid 21-hydroxylase [MIM 201910])
and TNXB (extracellular matrix protein [MIM 600985]).9
The C4 sequence in each module is usually functional
and can code for either of the two C4 paralogs, C4A (MIM
120810) or C4B (MIM 120820). C4A and C4B show 99%
sequence identity over 41 exons and are differentiated by
five conserved nucleotide changes in exon 26, causing
four isotype-specific amino acid substitutions at positions
1101to 1106: PCPVLD for C4A and LSPVIH for C4B.10
The amino acid substitutions result in different chemical
activities for C4A and C4B. C4A has a longer half life and
a higher affinity for amino groups, suggesting a role in
the clearance of immune complexes, whereas C4B binds
more effectively to hydroxyl groups, resulting in a reduced
half-life compared to that in C4A and implying a possible
role in membrane attack complex formation and defense
against bacterial pathogens.11 It has been suggested that
haplotypes harboring a single RCCX module representfection and Inflammatory Disease, Guy’s Hospital, King’s College London,
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the ancestral state of the locus and subsequent duplications
of the C4 gene, driven by selective pressures to strengthen
innate and adaptive immune responses, led to the diversifi-
cation of its paralogs and the CNV seen in themodern pop-
ulation.
Complete or homozygous deficiency of complement C4,
which is rare, is one of the strongest genetic risk factors for
SLE and results in lupus-like disease in approximately 80%
of the 28 known affected individuals12–14. Complement
component C4 is essential for the activation of the classical
and mannose-binding lectin complement pathways. As
such, C4 plays a vital role in the integrity of innate and
adaptive host immune responses, including protection
against bacterial pathogens through opsonisation of target
antigens and cell lysis through the formation of the
membrane attack complex, clearance of immune
complexes and apoptotic cell debris, and negative selec-
tion of autoreactive B cells.15
Partial C4 deficiency states have also shown association
with SLE, but despite much effort over the last 30 years,
it has not been established whether this association is
primarily causal or secondary to long-range LD across the
MHC region.15–18 Partial C4 deficiency can arise because
of CNV at the C4 locus (i.e., low C4 gene copy number
[GCN]) as well as mutations in the gene sequence, result-
ing in nonexpressed (or null) C4 alleles (C4AQ0 and
C4BQ0). The most frequent loss-of-function mutation is
that of a 2 bp CT insertion in exon 29 of the gene, which
causes a frameshift change, resulting in a premature stop
codon in exon 30.19 In healthy European populations,
partial and homozygous deficiencies of C4A and C4B are
frequent and occur as a consequence of haplotypes bearing
monomodular RCCX cassettes, which comprise either C4A
or C4B. Hence, the alternate C4 paralog will be physically
absent and not expressed. Monomodular RCCX cassettes
occur commonly, but not exclusively, on extended HLA-
DRB1*03:01 haplotypes.20 A monomodular RCCX
cassette, coding for a single C4B copy, lacking C4A and re-
sulting in C4A deficiency, is found on the extended A*01-
B*08-(C4A*Q0)-C4B1-DRB1*03:01 (B8) haplotype. This is
the most common HLA-DRB1*03:01 haplotype in
northern European populations and shows association
with SLE and many other autoimmune diseases. Because
of tight LD, it has not been possible to identify the location
of the causal variant(s) on this conserved haplotype. C4B
deficiency has shown association with SLE in Spanish pop-
ulations and frequently arises as a consequence of a mono-
modular RCCX cassette carrying a single C4A copy on the
A*30-B*18-C4A3-(C4B*Q0)-DRB1*03:01 (B18) haplotype,
which is observed at a higher frequency in the Spanish
population compared with northern Europeans.
In general, C4A and C4B GCNs were not directly deter-
mined in the aforementioned studies but inferred by
measuring relative plasma protein concentrations of C4A
and C4B (immunophenotyping). In 2007, a European-
American case-control study used Southern blot analysis
to determine total C4, C4A, and C4B GCN distributions446 The American Journal of Human Genetics 90, 445–456, March 9in SLE.21 This study demonstrated disease predisposition
with low C4A GCN, in addition to a protective effect
arising from high C4A GCN. No significant differences
were observed in the distribution C4B GCN.
Recent family and case-control SNP studies in SLE popu-
lations of northern European ancestry have identified
primary MHC class III association signals surrounding
the RCCX module that are independent of the HLA-
DRB1*03:01 class II region signal.22,23 We have previously
demonstrated that these class III region SNPs display
moderate correlation with monomodular C4A-deficient
haplotypes in healthy individuals from the UK and the
HapMap CEU cohort.24
Therefore, in this study we wanted to establish whether
genetically determined partial C4 deficiency states are
independent risk factors for SLE in northern and southern
Europeans or whether the association observed is due to
LD with MHC polymorphism elsewhere such as HLA-
DRB1*03:01 or class III region SNPs. In order to do so, we
have amalgamated C4 CNV, HLA-DRB1 (MIM 142857),
and MHC region SNP data from haplotypically diverse UK
and Spanish SLE populations in the largest study of C4
CNV in SLE to date. The different LD relationships between
MHC polymorphisms in the two cohorts should allow
determination of independent genetic risk. We have devel-
oped a high-throughput paralog ratio test (PRT) to reliably
determine C4 CNV genotypes.24 We have also developed
a paralog-specific restriction enzyme digest variant ratio
(REDVR) assay to detect the presence of the most common
cause of a C4 null allele—the 2 bp exon 29 CT insertion.25
One would expect enrichment of this indel in cases if
partial C4 deficiency states are indeed causal in SLE. Specif-
ically, we genotyped 2,207 subjects (1,028 SLE cases and
1,179 controls) for total C4 GCN, C4A GCN, C4B GCN,
and theC4 exon29 indel.High-density SNPdatawere avail-
able for all individuals, allowing us to explore SNP-C4CNV
correlations in the region. In addition, we have performed
multiple logistic regression analyses in the UK and Spanish
SLE cohorts to determine whether low complement C4
GCNs are independent of known MHC region SNP and
HLA-DRB1 associations as well as examining the region
for interaction effects between these markers.Subjects and Methods
Ethics Statement
This study was approved by the London Research Ethics
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del CSIC, Granada, Spain and Clinical Research Ethics Committee
of Vall d’Hebron University Hospital, Barcelona, Spain.
Study Cohorts
UK Cohort
The UK cohort comprised 501 UK SLE probands and 719 healthy,
unrelated individuals from the 1958 British Birth Cohort. All indi-
viduals had been previously genotyped to high-density at the
MHC with a custom Illumina panel.23 Four digit HLA-DRB1, 2012
genotypes were available for 481/501 (96%) of the cases. Two-digit
genotypes were available for 661/719 (92%) of the controls.
Spanish Cohort
The Spanish cohort comprised 527 Spanish SLE cases and 460
healthy, unrelated individuals; 2,553 ancestry informative
markers (AIMs) and 4,179 SNP genotypes across the MHC region
were available for all subjects. Samples were typed with a custom
Illumina panel as part of the IMAGEN consortium study26 or the
Illumina OMNI-1 array chip; 192 SLE subjects were genotyped
on both platforms with 100% concordance for all SNP genotypes.
Four-digit HLA-DRB1 genotypes were available for 199/527 (38%)
cases and 224/460 (48%) controls.
All SLE probands fulfilled the American College of Rheuma-
tology criteria for the classification of SLE.27 Written informed
consent was obtained from all study participants.
Complement C4 Paralog Ratio Test
We used our complement C4 PRT to determine total C4GCN, C4A
GCN, and C4B GCN in the UK cohort according to methodology
described previously24.
For the Spanish cohort, each plate run was normalized with 16
control samples. The six UK normalization samples were used in
addition to ten Spanish SLE samples with total C4, C4A, and C4B
GCN previously determined by Southern blot. The 16 samples
used for normalization covered copy-number genotypes of two to
six. Normalized PRT and REDVR A ratios for each plate were clus-
tered and genotype calls made for each sample, as previously
described.24
Complement C4 Exon 29 CT Insertion Assay
A high-throughput, paralog-specific REDVR assay was used to
genotype samples for the 2 bp CT insertion located in exon 29
of C4.25 The assay, combined with C4 GCN data, provided infor-
mation on the copy number of C4A and C4B genes harboring
the insertion in an individual.
HLA Genotyping
HLA typing was performed with Luminex One Lambda SSO.
Four-digit HLA-DRB1 typing was performed in 481 of 501 of UK
SLE cases (96%). The typing was performed at the Anthony Nolan
Trust, London, UK. Two-digit HLA-DRB1 data were obtained for
661 of the 719 UK controls (92%) from the 1958 British Birth
Cohort.
Four-digit genotyping forHLA-B (MIM 142830),HLA-DRB1, and
HLA-DQB1 (MIM 604305) was performed in the Spanish cohort at
Hospital Virgen del Rocı´o, Seville, Spain, and Hospital Virgen de
las Nieves, Granada, Spain. Four-digit HLA-DRB1 and HLA-DQB1
genotypes were available for 224/460 (48%) Spanish control
samples. Four-digit HLA-DRB1 and HLA-DQB1 genotypes were
available for 199/527 (38%) of the Spanish SLE cases.
C4 CNV/SNP Correlation
We tested for correlation between C4 GCN genotypes and
surrounding MHC SNPs by using standard linear regression as
described previously.24 We analyzed individuals with zero, one, or
two copies of C4A or C4B. In such individuals C4 GCN genotypes
can be downcoded as SNP genotypes assuming that the two-copy
individuals carry a single C4 gene on each chromosome: 0 for
a two-copy, 1 for a single-copy, and 2 for a zero-copy homozygote
of eitherC4AorC4B. Thiswouldallow investigationof the relation-
ships between low C4 copy alleles, which have shown associationThe Amewith SLE and surrounding SNPs. For C4A, 533 (74%) UK controls,
393 (78%) UK cases, 322 (73%) Spanish controls, and 347 (74%)
Spanish cases with C4A GCN of two or less were analyzed for C4A
GCN/SNP correlation. For C4B, 621 (86%) UK controls, 379
(75%) UK SLE cases, 360 (80%) Spanish controls, and 391 (84%)
Spanish SLE cases with C4B GCN of two or less were analyzed for
C4B GCN/SNP correlation. HLA alleles in both cohorts were re-
coded to SNP genotypes and included in the correlation analyses.
Correlation coefficients, r2, were calculated between C4 CNV data
and 1,230 MHC SNPs for the UK cohort and 4,178 MHC SNPs for
the Spanish cohort.SNP Quality-Control Filters
SNP quality-control (QC) filters for the UK cohort have been previ-
ously described.23 For the Spanish cohort, all QC analyses except
principal components analyses were performed with PLINK.28
Samples and SNPs were put forward for analysis if they met the
following QC filters: SNPs greater than 95% genotyping efficiency,
MAF greater than 1%, samples greater than 95% genotyping effi-
ciency, and PI-Hat scores less than 0.2 on identity-by-state analysis
with AIMs in order to exclude cryptic relatedness and duplicate
samples. SNPs were excluded for deviation from Hardy-Weinberg
equilibrium in controls on the basis of a false discovery rate
(FDR) of 0.05 (n ¼ 61). In order to correct for population stratifica-
tion, samples were excluded if they were outliers on principal
components analysis with post-QC AIMs (performed with EIGEN-
STRATand defined as greater than 4 standard deviations (SDs)from
the mean).29 The genomic inflation factor (lGC) was calculated
with the post-QC AIMs after correction for population stratifica-
tion (lGC ¼ 1.04).Statistical Analyses
The mean, SD and p value for C4 copy-number frequencies
between cases and controls and between cohorts were calculated
with SPSS (SPSS, Chicago, IL, USA). One-way analysis of variance
(ANOVA) was performed in SPSS to test for differences in integer
GCNs of total C4, C4A, and C4B across SLE cases and controls.
To estimate the odds ratio (OR) for low (0 or 1) and high (3 or
more) C4A and C4B GCNs relative to a C4A or C4B GCN of two,
we performed logistic regression by using the glm function in
the statistical package R, with copy-number class (low or high)
coded as a categorical variable and GCN of two used as a reference.
We performed a test for heterogeneity of odds ratios for the two
cohorts by coding up cohort as a binary variable and testing for
interaction between the cohort and OR while letting the intercept
term and the term for the ancestry covariate vary between groups.
This was performed in R and tests against the null-hypothesis of
equal ORs.
The statistical power to detect an association for the C4A CT
insertion for the Spanish and UK cohorts is 57% and >99%,
respectively, assuming an odds ratio (OR) of 1.93 for the Spanish
and an OR of 2.13 for the UK at the 5% significance level. The
assumed effect sizes are equivalent to the ORs for C4A zero-copy
(nonexpressed) alleles in each cohort.
Single-marker association analyses employing logistic regres-
sion (LR) and multiple logistic regression (MLR) were performed
via PLINK for the five markers chosen for analysis: rs558702
(the most highly associated SNP in the single-marker analysis in
both cohorts), C4A, C4B, HLA-DRB1*03, and HLA-DRB1*15. Prin-
cipal component one (PC1) was used as a covariate in all analyses
to correct for population substructure. Only individuals with C4Arican Journal of Human Genetics 90, 445–456, March 9, 2012 447
Figure 1. Total Complement C4, C4A, and C4B
GCN Distributions in UK and Spanish SLE
From top to bottom, the histograms demonstrate
total complement C4, C4A, and C4B GCN distri-
butions in healthy controls (blue) and SLE cases
(red) from the UK and Spain.and C4B GCNs of zero, one, or two were included in these anal-
yses. We performed MLR to determine independent effects for
each of the five chosen markers at the MHC; every marker was
tested for association conditional on PC1 as a covariate and
each of the other four markers as a covariate, resulting in four tests
for every marker used as a covariate. In order to correct for
multiple testing, we permuted the data 10,000 times for each of
the five sets of tests. We included genotypes for the well-estab-
lished SLE risk alleles, HLA-DRB1*03 and HLA-DRB1*15 in the
UK cohort and tag SNPs for HLA-DRB1*03 and HLA-DRB1*15 in
the Spanish cohort (rs2187668, r2 ¼ 0.79 and rs3135391, r2 ¼
0.82, respectively). We looked for interactions between C4A and
C4B and independently associated variants across the MHC by
using the glm function in R. We examined LD relationships
between SNPs and HLA alleles in each cohort by calculating
the correlation coefficient, r2, by using the Tagger algorithm in
Haploview.30
Stepwise logistic regression with the Bayesian information crite-
rion (BIC) was used to determine which of the five variables448 The American Journal of Human Genetics 90, 445–456, March 9, 2012(rs558702, C4A, C4B, HLA-DRB1*03, and HLA-
DRB1*15) best explained disease status. This
analysis was performed in R. Along with the
model return by the stepwise procedure, we
also checked the BIC for models within the
vicinity of the best model (by adding and sub-
tracting variables).
Results
Complement C4 GCN Range in UK
and Spanish SLE Cohorts
Using the C4 PRT assay, we determined the
GCN for total C4, C4A, and C4B in 501 UK
SLE cases, 719 UK controls, 527 Spanish
SLE cases, and 460 Spanish controls. We
have previously reported C4 copy-number
ranges in UK and Spanish control popula-
tions.25 These data are summarized here
for comparison with the UK and Spanish
SLE case statistics.
UK SLE Cases and Controls
Demonstrate a Wide Range of C4
CNV Corroborating Previous
European-American SLE Data
In the UK cohort, total C4GCN varied from
two to six in controls, and from two to eight
in cases (Figure 1 and Table 1). Both C4A
GCN and C4B GCN ranged from zero to
four in controls and from zero to five incases.Mean totalC4GCNandC4AGCNwere lower in cases
compared to controls, whereas mean C4B GCN was higher
in cases compared to controls. These data are consistent
with those previously observed in European-American SLE
populations.21Spanish Populations Display a Broader Range of C4
CNV Compared to the UK Population
Within the Spanish cohort, 11/460 controls and 63/527
SLE cases were excluded for relatedness or because they
were population outliers, resulting in a post-QC cohort
size of 464 cases and 449 controls.
In both Spanish controls and cases, total C4 GCN varied
from two to eight, identical to that observed in UK cases
but less than in UK controls (Figure 1 and Table 1). C4A
and C4B GCN ranges were similar in UK and Spanish
cohorts. Mean total C4, C4A, and C4BGCNs were all lower
Table 1. Total Complement C4, C4A, and C4B GCN Frequencies in UK and Spanish SLE Cohorts
GCN Range 0 1 2 3 4 5 6 7 8 Mean (±SD) p Valuea
C4 GCN
UK SLE (n ¼ 501) 2–8 – – 36 (7.18%) 158 (31.53%) 210 (41.96%) 70 (13.97%) 25 (4.99%) 1(0.19%) 1(0.19%) 3.79 5 0.98 0.046
UK controls (n ¼ 719) 2–6 – – 25 (3.47%) 168 (23.36%) 385 (53.00%) 137 (19.00%) 4 (0.55%) 0 0 3.89 5 0.76 0.046
Spanish SLE (n ¼ 464) 2–8 – – 28 (6.03%) 141 (30.83%) 213 (45.90%) 67 (14.40%) 11 (2.37%) 3(0.64%) 1(0.21%) 3.80 5 0.92 <0.001
Spanish controls
(n ¼ 449)
2–8 – – 19 (4.23%) 86 (19.15%) 210 (46.77%) 93 (20.70%) 32 (7.12%) 7(1.55%) 2(0.44%) 4.13 5 1.02 <0.001
C4A GCN
UK SLE 0–5 26 (5.18%) 165 (32.90%) 202 (40.30%) 88 (17.50%) 18 (3.59%) 2(0.40%) 0 – – 1.82 5 0.93 <0.001
UK controls 0–4 9 (1.25%) 149 (20.70%) 375 (52.20%) 143 (19.90%) 43 (5.90%) 0 0 – – 2.08 5 0.83 <0.001
Spanish SLE 0–5 5 (1.07%) 111 (23.90%) 231 (49.80%) 99 (21.30%) 13 (2.80%) 5(1.07%) 0 – – 2.04 5 0.85 0.007
Spanish controls 0–6 5 (1.11%) 54 (12.02%) 263 (58.60%) 107 (23.80%) 16 (3.6%) 3(0.70%) 1(0.22%) – – 2.19 5 0.78 0.007
C4B GCN
UK SLE 0–5 13 (2.60%) 125 (24.90%) 241 (48.10%) 110 (21.90%) 11 (2.20%) 1(0.20%) – – – 1.96 5 0.82 <0.001
UK controls 0–4 26 (3.60%) 185 (25.70%) 410 (57.00%) 94 (13.00%) 4 (0.60%) 0 – – – 1.81 5 0.72 <0.001
Spanish SLE 0–4 14 (3.00%) 170 (36.60%) 207 (44.60%) 62 (13.40%) 11 (2.40%) 0 – – – 1.75 5 0.81 0.019
Spanish controls 0–5 12 (2.70%) 117 (26.00%) 231 (51.40%) 64 (14.30%) 24 (5.30%) 1(0.20%) – – – 1.94 5 0.86 0.019
at test p value.
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Table 2. Mean Total Complement C4, C4A, and C4B GCN in UK and
Spanish SLE Cohorts
GCN Range Mean (± SD) p Valuea
C4 GCN
UK SLE (n ¼ 501) 2–8 3.79 5 0.98 0.864
Spanish SLE (n ¼ 464) 2–8 3.80 5 0.92
UK controls (n ¼ 719) 2–6 3.89 5 0.76 <0.001
Spanish controls (n ¼ 449) 2–8 4.13 5 1.02
C4A GCN
UK SLE 0–5 1.82 5 0.93 <0.001
Spanish SLE 0–5 2.04 5 0.85
UK controls 0–4 2.08 5 0.83 0.019
Spanish controls 0–6 2.19 5 0.78
C4B GCN
UK SLE 0–5 1.96 5 0.82 <0.001
Spanish SLE 0–4 1.75 5 0.81
UK controls 0–4 1.81 5 0.72 0.007
Spanish controls 0–5 1.94 5 0.86
at test p value.in Spanish cases compared to controls. Mean total C4,
C4A, and C4B GCNs were higher in Spanish controls
compared to UK controls (Table 2). There was no signifi-
cant difference between total C4 GCN in UK and Spanish
SLE cases. C4A and C4B GCNs demonstrated contrasting
effects in SLE cases between the two cohorts with greater
mean values in Spanish cases compared to UK cases for
C4A and lower levels in Spanish cases compared to UK
cases for C4B (Table 2).
Similar C4A but Differential C4B Copy-Number
Associations in UK and Spanish SLE
We compared the total C4, C4A, and C4B integer copy-
number distributions in cases and controls in both cohorts
by using a one-way ANOVA. We found significant differ-
ences between the distributions of total C4 (UK: p <
0.001, Spanish: p < 0.001), C4A (UK, p < 0.001 and
Spanish, p ¼ 0.001) and C4B (UK, p < 0.001 and Spanish,
p ¼ 0.005) in SLE cases compared to controls in both the
UK and Spanish cohorts.
In order to delineate the effects of C4 integer GCN on
risk of disease, we estimated the risk of low (0 or 1) or
high (3 or more) copy number of C4A and C4B relative
to a GCN of 2 (Table 3). Within the UK cohort, we found
that low C4A GCN was significantly associated with risk
of SLE, compared to a GCN of 2 (OR ¼ 2.27, 95% confi-
dence interval [CI] 1.72–2.99, p ¼ 1.14 3 109), whereas
high C4A copy number demonstrated no association
with disease. With regard to C4B, there was no association
between low C4B GCN and UK SLE, whereas high copy450 The American Journal of Human Genetics 90, 445–456, March 9numbers conferred significant risk compared to a GCN of
2 (OR ¼ 2.07, 95% CI 1.51–2.83, p ¼ 4.44 3 106).
In parallel with the UK data, the Spanish cohort demon-
strated significant SLE risk with low C4A GCN (OR ¼ 2.22,
95% CI 1.56–3.20, p ¼ 1.14 3 105), whereas high C4A
copies were not associated with disease susceptibility.
However, in contrast to the UK data, the Spanish cohort
demonstrated significant risk between low C4B GCN and
SLE (OR ¼ 1.58, 95% CI 1.18–3.25, p ¼ 1.80 3 103) but
no association with high C4B GCN.
We performed a test of heterogeneity on the odds ratios
for C4A and C4B high- and low-GCN classes in the UK
and the Spanish populations. The odds ratios for high
and low C4A GCNs were not significantly different
between cohorts; however, the odds ratios for high and
low C4B GCN were significantly heterogeneous between
cohorts (low C4B p ¼ 0.01, high C4B p ¼ 1.81 3 104).
The Loss-of-Function C4A Exon 29 CT Insertion Is Not
Associated with SLE in UK and Spanish Populations
All samples were tested for the presence of a 2 bp CT inser-
tion in exon 29, which results in a nonfunctional C4 allele
(Table S1, available online, and Figure 2). We have previ-
ously shown that 30/719 (4.17%) UK controls harbored
the insertion in C4A.25 This is similar to the frequency of
the CT insertion in UK SLE cases (21/501 [4.19%] p ¼
0.55). No C4B insertions were observed in UK controls,
whereas one individual carried the exon 29 CT insertion
in C4B in the UK SLE cases.
In the Spanish controls, eight samples out of 449
(1.78%) carried the insertion in C4A, lower than that
observed in UK controls. The frequency of C4A CT
insertions in Spanish SLE cases was 1.29%, not signifi-
cantly different from the frequency observed in Spanish
controls but less than that observed in UK cases. A
single individual in the Spanish controls carried the inser-
tion in C4B, along with one additional functional C4B
copy. No C4B insertions were observed in Spanish SLE
cases.
Whereas the frequency of the C4A exon 29 CT insertion
is significantly different between healthy controls from the
UK and Spain (p ¼ 0.014) and SLE cases from the UK and
Spain (p ¼ 0.011), we observed no significant differences
in the frequency of the insertion between cases and
controls within the two cohorts. There is no evidence of
enrichment of the C4A exon 29 CT insertion in SLE cases
compared to controls. Therefore, this loss-of-function
mutation does not predispose to SLE in UK and Spanish
populations.
Neither MHC Region SNPs nor HLA-DRB1 Alleles
Provide Surrogate Markers for C4 Copy-Number
Variants in UK and Spanish SLE Cohorts
We used linear regression to test for correlation between
C4A and C4B GCN and surrounding MHC polymorphism
in each cohort. We have previously reported SNP/C4 CNV
correlations for the UK control population and SNP/C4, 2012
Table 3. High and Low C4A and C4B GCN Effects in UK and Spanish SLE Cohorts
UK OR 95% CIa p Valueb Spain OR 95% CI p Value
OR Heterogeneity
p Valuec
low C4A GCN 2.27 1.72–2.99 1.14 3 109 low C4A GCN 2.22 1.56–3.20 1.14 3 105 0.99
high C4A GCN 1.07 0.79–1.43 0.63 high C4A GCN 1.04 0.77–1.42 0.76 0.94
low C4B GCN 1.09 0.85–1.41 0.49 low C4B GCN 1.58 1.18–3.26 1.80 3 103 0.01
high C4B GCN 2.07 1.52–2.84 4.44 3 106 high C4B GCN 0.92 0.65–1.31 0.63 1.81 3 104
aOdds ratio 95% CI.
bLogistic regression p value.
cTest of heterogeneity of odds ratios in cohorts p value (see Statistical Analyses).exon 29 CT indel correlations for the UK and Spanish
controls.24,25 The data are summarized below for compara-
tive purposes in addition to the novel Spanish control pop-
ulation SNP/C4 CNV correlations, and novel UK and
Spanish SLE case SNP/C4 CNV and SNP/C4 exon 29 CT in-
del correlations.
SNP/C4A CNV Correlation Is Greater in UK Compared
to Spanish Data Sets
In both UK cases and controls, the highest SNP/C4A CNV
correlation values were observed for SNPs in class III, on
either side of the RCCX module (Figure S1 and Table S2).
The best correlated SNPs were rs558702, (intronic C2
[MIM 613927], r2 ¼ 0.61 in controls and 0.58 in cases),
the intronic SNPs, rs3131378 and rs3131379, in MSH5
(MIM 603382) (r2 ¼ 0.60 in controls and 0.56 in cases)
and the intronic SNP, rs1269852, in ATF6B (MIM
600984) (r2 ¼ 0.59 in cases and controls). These four
SNPs are in strong LD and have demonstrated association
with SLE in a high-density SNP study across the MHC
and an SLE GWAS.23,31 The HLA-DRB1*03:01 allele
showed moderate correlation in UK cases (r2 ¼ 0.49) and
controls (r2 ¼ 0.45 for HLA-DRB1*03).
Lower SNP/CNV correlation coefficents were observed
in the Spanish cohort compared to that of the UK, most
likely reflecting the broader haplotypic diversity at the
MHC seen in the former.32Within the Spanish population,
higher correlation values were observed for the same
SNPs in cases compared to controls (Figure S1 and
Table S2). The best correlated SNPs in the Spanish cohort
were rs558702 (r2 of 0.44 for cases and 0.20 for controls)
and rs3131379 (r2 ¼ 0.44 in cases and 0.19 in controls).
These SNPs are identical to the best correlated C4A
CNV SNPs in the UK cohort and have recently shown
primary association with SLE in a high-density Spanish
MHC SNP study.26 The HLA-DRB1*03:01 allele showed
weaker correlation with C4A CNV compared to the UK
cohort (r2 ¼ 0.12 in Spanish cases and r2 ¼ 0.03 in Spanish
controls).
SNP/C4A CNV correlation coefficients observed in these
two populations show that MHC region SNPs cannot be
used as surrogate markers for the C4A zero-copy state in
either of the two populations and confirm the results of
our previous study in healthy populations.24The AmeSNP/C4B CNV Correlations Are Low in UK and
Spanish Populations
The correlation values between surrounding MHC region
SNPs and C4B genotypes were low for all cohorts
(Figure S2 and Table S3).
In UK cases and controls, the highest correlation values
were observed with the SNP, rs605203, located 50 SLC44A4
(MIM 606107) (r2 ¼ 0.11 controls, r2 ¼ 0.12 cases) and the
intronic SNP, rs659445, in EHMT2 (MIM 604599) (r2 ¼
0.11 controls, r2 ¼ 0.12 cases) telomeric to the RCCX
module.
Slightly higher SNP/C4B CNV correlation values were
observed in the Spanish cohort. Themost highly correlated
markers were an intronic SNP in NOTCH4, rs379464 (r2 ¼
0.19 controls and r2 ¼ 0.18 cases), and rs9267785 in RDBP
(MIM 154040) (r2 ¼ 0.20 controls and r2 ¼ 0.19 cases).
Correlation values for all SNPs were below 0.3 in the UK
and Spanish cohorts demonstrating that haplotypes lack-
ing C4B genes are diverse in both populations.
SNP/C4A Exon 29 CT Insertion Correlations Are Low
in UK and Spanish Cohorts
In both UK cases and controls the top correlated SNPs with
the C4A exon 29 insertion were located in the class III
region, telomeric to the RCCXmodule (Figure S3 and Table
S4). The SNP with the highest correlation value was
rs2734331, a synonymous SNP in SKIV2L (MIM 600478)
(0.43 for controls and r2 ¼ 0.40 for cases).
The top correlated SNPs for Spanish controls were also
located in the MHC class III region(best SNP, rs2228088,
a synonymous variant in TNF [MIM 191160]; r2 ¼ 0.25).
Low correlation values were seen in the Spanish SLE cases.
The top correlated SNPs were rs11752643 downstream of
HLA-DQB1 (r2¼ 0.13) and rs9469027 intronic LST1 in class
III ([MIM 109170]; r2 ¼ 0.11).
Complement C4A and C4B GCN Variants Are Not
Independent Genetic Risk Factors for SLE in UK and
Spanish Populations
We analyzed 501 UK SLE cases and 719 controls by using
logistic regression and MLR on 1230 MHC SNPs,
HLA-DRB1 alleles and C4A and C4B GCN genotypes
(Table 4). The most strongly associated marker in the
univariate analysis was rs558702, (intronic C2, in the classrican Journal of Human Genetics 90, 445–456, March 9, 2012 451
Figure 2. Frequency of the Complement C4A exon 29 CT Inser-
tion in UK and Spanish SLE Cohorts
The histogram shows the frequency of the loss-of-function
complement C4A exon 29 CT insertion in healthy controls
(blue) and SLE cases (red) from the UK and Spain.III region of the MHC, OR ¼ 2.61, 95% CI 2.07–3.29,
nominal p ¼ 4.26 3 1016) and other SNPs in strong LD
that all show moderate correlation with C4A CNV and
have previously demonstrated association with SLE in
northern and southern European populations.23 The C4A
zero-copy allele and HLA-DRB1*03 were also associated
with lupus in the single-marker analysis (C4A OR ¼ 2.13,
95% CI 1.68–2.70, nominal p ¼ 5.27 3 1010, HLA-
DRB1*03 OR ¼ 2.55, 95% CI ¼ 2.03–3.21, nominal p ¼
1.43 3 1015). C4B zero-copy and HLA-DRB1*15 alleles
were not associated with SLE in the univariate analysis.
Next, we performed MLR to assess the independence of
these five markers in UK SLE (Table 4). Conditioning on
the SNP, rs558702, or HLA-DRB1*03, abrogated the effect
of low C4A GCN. In contrast to the univariate analysis,
significant association was observed with HLA-DRB1*15,
whereas that of C4B GCN was unchanged. Conversely, if
C4A is used as a covariate in the MLR, rs558702 and HLA-
DRB1*03 remain significantly associated with SLE. Condi-
tioning on C4B or HLA-DRB1*15 had no effect on the
association of any of the four remainingmarkers inUK SLE.
Within the Spanish SLE cohort, 4,178 MHC region SNPs
and C4A and C4B GCN genotypes were analyzed in 464
SLE cases and 449 controls. In addition, rs2187668 and
rs3135391 were used as proxy SNPs for HLA-DRB1*03:01
and HLA-DRB1*15:01, respectively, in this population. As
observed in the UK cohort, the most strongly associated
univariate marker in the Spanish group was rs558702
(OR ¼ 2.92, 95% CI 1.93–4.45, nominal p ¼ 6.73 3 107).
This SNP demonstrated moderate correlation with C4A
CNV in the Spanish population. HLA-DRB1*03:01, HLA-
DRB1*15:01, C4A and C4B zero-copy alleles were also asso-
ciated with SLE in this population in the single-marker
analysis. When rs558702 is used as a covariate, the effects
of C4A GCN and HLA-DRB1*03:01 were not significant.
However, the C4B andHLA-DRB1*15:01 association results452 The American Journal of Human Genetics 90, 445–456, March 9remained largely unchanged. Conditioning on HLA-
DRB1*15:01, C4A or C4B had little effect on the univariate
results, whereas the use of HLA-DRB1*03:01 as a covariate
abrogated the effect of C4A, showed a trend for reducing
the effect size of rs558702, and did not influence the asso-
ciation signals observed for C4B or HLA-DRB1*15:01.
These data demonstrate that the low C4AGCN association
observed in UK and Spanish SLE is not primary but due to
LD of the C4A zero-copy allele with polymorphism else-
where in the MHC region tagged by rs558702 and HLA-
DRB1*03.
We found no evidence of interaction effects between
C4A, C4B, rs558702, HLA-DRB1*03, and HLA-DRB1*15
in UK and Spanish SLE.
Model selection with the BIC identified the variables
HLA-DRB1*03þHLA-DRB1*15 alone as the best fit to the
data in the UK cohort (BIC¼ 1,570.23). However, the addi-
tion of rs558702 (BIC ¼ 1,572.59) or C4B (BIC ¼ 1,572.75)
to these two alleles were also a good fit. The addition of
C4A, however, is strongly rejected (BIC ¼ 1,577.04) in
favor of HLA-DRB1*03þHLA-DRB1*15 alone (estimated
Bayes factor in favor of HLA-DRB1*03þHLA-DRB1*15
alone ¼ 33). In the Spanish data, the variables
rs558702þC4BþHLA-DRB1*15 were the best fit (BIC ¼
1,250.42). The addition of HLA-DRB1*03 (BIC ¼ 1,254.7)
or C4A (BIC ¼ 1,254.9) to these three alleles was also re-
jected in favor of rs558702þC4BþHLA-DRB1*15 alone
(Bayes factor of 8.5 and 9.4, respectively).Discussion
In order to determine whether partial complement C4 defi-
ciency is an independent genetic risk factor for SLE, we
have investigated C4 CNV in the context of HLA-DRB1
and MHC region SNP polymorphism in the largest and
most comprehensive complement C4 study to date. For
the first time, we have examined complement C4 CNV
in a southern European Spanish SLE cohort in conjunction
with that of a northern European UK SLE population. We
have used our previously validated PRT to assess total C4,
C4A, and C4B GCN variation in 965 SLE cases and 1,168
healthy individuals (post-QC). In addition, we have geno-
typed the most common C4 nonsense mutation—an exon
29 CT insertion—in all study subjects to assess disease asso-
ciation.
In this study, we have clearly shown that genetically
determined partial C4 deficiency states are not indepen-
dent genetic risk factors for SLE in UK and Spanish popula-
tions. The haplotypic diversity within the MHC region
between the northern and southern European cohorts,
consequent on ancestry and environment, has allowed
delineation of such effects. These results are further corrob-
orated by the lack of association shown by the loss-of-func-
tion C4A exon 29 CT insertion in both SLE cohorts. Hence,
although complete homozygous deficiency of comple-
ment C4 is one of the strongest genetic risk factors for, 2012
Table 4. Single-Marker and Multiple Logistic Regression Analysis of MHC Polymorphism in UK and Spanish SLE
Single Marker Conditioned on rs558702 Conditioned on C4A Conditioned on C4B Conditioned on DRB1*03 Conditioned on DRB1*15
UK Spain UK Spain UK Spain UK Spain UK Spaina UK Spaina
rs558702
MAFb 0.11 0.04
OR (95%CI) 2.61
(2.07–3.29)
2.92
(1.91–4.45)
– – 2.46
(1.66–3.64)
2.49
(1.46–4.24)
2.84
(2.17–3.71)
3.27
(2.03–5.26)
1.58
(1.04–2.39)
2.30
(1.41–3.75)
2.73
(2.15–3.48)
3.07
(2.00–4.71)
p Valuec 1.00 3 104 1.00 3 104 – – 1.00 3 104 2.90 3 103 1.00 3 104 1.00 3 104 0.11 2.40 3 103 1.00 3 104 1.00 3 104
C4A
MAF 0.16 0.10
OR (95%CI) 2.13
(1.68–2.70)
1.93
(1.36–2.72)
1.09
(0.74–1.60)
1.24
(0.81–1.90)
– – 2.24
(1.69–2.96)
2.10
(1.38–3.19)
1.27
(0.91–1.79)
1.58
(1.10–2.28)
2.20
(1.72–2.82)
1.95
(1.38–2.76)
p Value 1.00 3 104 1.20 3 103 0.98 0.77 – – 1.00 3 104 1.50 3 103 0.49 0.05 1.00 3 104 8.00 3 104
C4B
MAF 0.19 0.19
OR (95%CI) 1.06
(0.84–1.32)
1.55
(1.19–2.02)
1.28
(1.01–1.63)
1.74
(1.32–2.29)
1.63
(1.14–2.34)
1.59
(1.13–2.25)
– – 1.12
(0.88–1.43)
1.40
(1.09–1.88)
1.05
(0.83–1.33)
1.61
(1.23–2.11)
p Value 0.99 4.70 3 103 0.18 6.00 3 104 0.02 0.03 – – 0.80 0.04 0.98 2.00 3 103
DRB1*03
MAF 0.13 0.12
OR (95%CI) 2.55
(2.03–3.21)
1.78a
(1.36–2.33)
1.77
(1.18–2.64)
1.33a
(0.97–1.82)
2.13
(1.51–3.00)
1.65a
(1.20–2.26)
2.64
(2.04–3.41)
1.63a
(1.21–2.20)
– – 2.78
(2.19–3.51)
1.94a
(1.47–2.55)
p Value 1.00 3 104 2.00 3 10-4a 0.02 0.24a 1.00 3 104 7.10 3 103a 1.00 3 104 4.00 3 103a – – 1.00 3 104 1.00 3 104a
DRB1*15
MAF 0.14 0.08
OR (95%CI) 1.23
(0.98–1.55)
1.58a
(1.13–2.22)
1.46
(1.15–1.86)
1.71a
(1.22–2.41)
1.22
(0.94–1.59)
1.57a
(1.07–2.30)
1.25
(0.96–1.65)
1.79a
(1.22–2.64)
1.53
(1.20–1.95)
1.83a
(1.30–2.58)
– –
p Value 0.27 0.03a 7.40 3 103 8.10 3 103a 0.39 0.08a 0.24 0.01a 2.00 3 103 1.50 3 103a – –
aTag SNPs were used as surrogate markers for the HLA-DRB1*03 and HLA-DRB1*15 alleles in the Spanish cohort because of the low proportion of samples with available HLA-DRB1 genotypes in this cohort. The SNP, rs2187668,
which was used as a surrogate marker for the HLA-DRB1*03 allele, demonstrated a correlation coefficient, r2, of 0.79 with the HLA-DRB1*03 allele in 34 Spanish controls of known HLA-DRB1 genotype. The SNP, rs3135391, was
used as a surrogate marker for the HLA-DRB1*15 allele, r2 ¼ 0.82 in 400 Spanish controls.
bMinor allele frequency.
cp value permuted 10,000 times.
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SLE, partial C4 deficiency states do not predispose to
disease. These data parallel the reported associations
between SLE and C1q deficiency. C1q is also an early
complement cascade component and initiates the classical
complement pathway by binding immunoglobulin.
Complete homozygous deficiency of C1q is the strongest
genetic risk factor for SLE known thus far, and approxi-
mately 90% of affected individuals develop lupus or
lupus-like disease.15 However, subjects who are heterozy-
gous for C1qnonsensemutations donot show apropensity
for autoimmunity. In conjunction, these data suggest that
complete lack of early classical complement cascade
components are important in susceptibility to SLE but
that these deleterious effects can be overcome by partial
expression of these proteins.
The molecular mechanisms underlying susceptibility to
SLE as a consequence of complete C4 deficiency have not
been fully elucidated. Mice deficient in complement
component C4 demonstrate lupus-like disease in a strain-
dependent manner, therefore complete C4 deficiency itself
is not sufficient to cause SLE—a permissive genetic back-
ground is required.33 It has been suggested that deficiency
of C4A rather than C4B is important in the development of
SLE because of the greater efficiency of C4A in handling
immune complexes.34 However, both C4A and C4B levels
vary in parallel with disease activity, suggesting that there
is no selective utilization of C4A over C4B.35 Moreover,
published reports have described associations between
complete C4A deficiency as well as complete C4B defi-
ciency states and immune complex disease.36 A number
of hypotheses, which are not mutually exclusive, have
been put forward to explain the association of C4 defi-
ciency with SLE. These include failure to clear apoptotic
cell debris, breakdown in peripheral tolerancemechanisms
caused by dendritic cell dysfunction, and failure of central
tolerance mechanisms where autoreactive B lymphocytes
escape to the periphery because of defective negative selec-
tion.33,37 None of these proposals are predicated on the
differential chemical properties observed between C4A
and C4B, thus the data presented herein are consistent
with these views.
The reasons underlying the difficulty in demonstrating
an independent genetic effect for partial C4 deficiency in
SLE over the past 30 years are manifold. Partial C4 defi-
ciency was first identified as either a lack of or a reduced
serum concentration of C4A or C4B based on the assump-
tion that each chromosome 6 encoded a single copy of
C4A and C4B. Hence, the resulting immunophenotyping
data that were used as surrogate markers for genetic varia-
tion at the locus failed to account for CNVat the locus. It is
now clear that low serum C4 levels frequently arise as
a consequence of the normal CNV observed at the C4
locus. Moreover, serum C4 is consumed in active lupus,
further confounding the results of immunophenotyping
studies. In order to accurately determine partial C4 defi-
ciency status, therefore, it became necessary to directly
interrogate the genome for C4 CNV. Studies using454 The American Journal of Human Genetics 90, 445–456, March 9Southern blot analysis to determine C4 CNV have
confirmed the association of low C4A GCN with SLE in
populations of European-American ancestry but have
failed to account for the effects of LD in the MHC
region.21
The C4 CNVassociation results in our UK SLE cohort are
similar to those previously described in European-Amer-
ican SLE cohorts.21 The distribution of total C4 and C4A
GCN is skewed toward the lower range in SLE cases
compared to the range in controls such that significantly
lower mean total C4 and C4AGCNs were observed in cases
compared to controls. A broader range of total C4, C4A,
and C4B CNV was observed in the Spanish population, re-
flecting the greater haplotypic diversity of this southern
European population.32 In common with UK SLE, mean
total C4 GCN and C4A GCN were significantly lower in
Spanish cases than controls. Contrary to the UK data,
C4B GCNs were also skewed to the lower copy range in
Spanish cases compared to the ranges in Spanish controls,
and the mean C4B GCN was significantly lower in the
former than in the latter. The predominance of low C4B
copy-number haplotypes in the Spanish cases is likely
correlated with the prevalence of the SLE risk A*30-B*18-
C4A3-(C4B*Q0)-DRB1*03:01 (B18) haplotype in this
population. The frequency of the HLA-DRB1*03 allele
was 12.85% in UK controls and 10.94% in Spanish
controls. Whereas HLA-B*18 occurred in conjunction
with 7.25% of HLA-DRB1*03 haplotypes in the UK
controls, 32% of HLA-DRB1*03 haplotypes in the Spanish
controls harbored HLA-B*18 and consequently did not
carry C4B.
The association results observed for C4A CNVare similar
in both UK and Spanish cohorts: low C4A GCN signifi-
cantly predisposes to SLE, whereas high C4A GCN is not
associated with disease in either cohort. On the other
hand, low C4B GCN shows no association in the UK SLE
cohort, but demonstrates significant risk in the Spanish
cohort. Conversely, high C4B copy numbers demonstrate
significant risk the UK SLE cohort, whereas no association
is observed in the Spanish cohort. Although the low C4A
GCN risk effect is consistent across the cohorts and could
be primary or due to the LD with causal variation, the
lack of consistency of C4B GCN effects across the cohorts
suggests that C4B CNV effects in SLE are secondary to LD
with as yet undefined polymorphisms within the MHC.
The SNP/CNV correlation analyses presented thus far
have used low C4 GCN as covariates (zero, one, and two
copies). We were not able to find any significant correla-
tions specifically between high C4B copy numbers and
HLA-DRB1 alleles or surrounding SNPs (data not shown).
However, as high C4B integer copy number can represent
a number of copy-number haplotypes, it is difficult to
establish such correlations.
A previous study that investigated the role of C4 CNV in
European-American SLE demonstrated disease predisposi-
tion with low C4A GCN and protection with high C4A
GCN.21 We confirm that low C4A GCN predisposes to, 2012
SLE in UK and Spanish populations. However, high C4A
GCNs did not confer protection in either population
when compared to a GCN of two. The protective effect
attributed to high C4A GCN in the previous study was
probably due to the confounding risk effects of low C4A
GCN.
In summary, we have conclusively shown that partial C4
deficiency states secondary to low C4A or C4BGCN are not
independent genetic risk factors for SLE. This study high-
lights the utility of interrogating ancestrally and thus hap-
lotypically diverse populations in order to resolve genetic
association signals through exploitation of differential
LD patterns.Supplemental Data
Supplemental Data include five figures and four tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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